J. Wang

发表

THU0657 Effects of adalimumab initiation on corticosteroid utilisation and medical costs among patients with rheumatoid arthritis

J. Griffith, C. Kaplan, A. Postlethwaite, 2018, THURSDAY, 14 JUNE 2018.

POS1174 HYPERINFLAMMATION AND CLINICAL OUTCOMES FOR PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES HOSPITALIZED FOR COVID-19: A COMPARATIVE COHORT STUDY

Hyon K. Choi, J. Sparks, E. Gravallese, 2021, Annals of the Rheumatic Diseases.

Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial

J. Frane, T. Lipman, A. Martini, 2014 .

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)

K. Minden, A. Martini, R. Burgos-Vargas, 2013, Pediatric Rheumatology.